Stockscreener 앱 받기
19.57
0.41%
0.08
시장 영업 전:
24.72
5.15
+26.32%
전일 마감가:
$19.49
열려 있는:
$19.67
하루 거래량:
1.42M
Relative Volume:
0.96
시가총액:
$1.79B
수익:
$12.59M
순이익/손실:
$-212.39M
주가수익비율:
-6.343
EPS:
-3.0853
순현금흐름:
$-185.92M
1주 성능:
-0.96%
1개월 성능:
+12.28%
6개월 성능:
+99.90%
1년 성능:
+49.73%
1일 변동 폭
$18.81
$19.82
1주일 범위
$18.81
$20.80
52주 변동 폭
$5.1501
$20.80
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
19.57 | 1.79B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 개시 | Truist | Buy |
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Immunome rises after positive data from experimental tumor treatment - TradingView — Track All Markets
Immunome stock surges after positive Phase 3 trial results By Investing.com - Investing.com Canada
Immunome Announces Positive Phase 3 Trial Results - TipRanks
Immunome's experimental drug meets main goal in late-stage study - marketscreener.com
Immunome Inc Announces Positive Phase 3 RINGSIDE Trial Results - TradingView — Track All Markets
Immunome (Nasdaq: IMNM) posts 84% risk cut in Phase 3 desmoid tumor trial - Stock Titan
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - BioSpace
What analysts say about Immunome Inc stockStock Buyback Announcements & Outstanding Growth Strategies - earlytimes.in
Immunome to disclose Phase 3 RINGSIDE trial results for desmoid tumors - Investing.com India
Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. $IMNM Stock Holdings Decreased by Redmile Group LLC - MarketBeat
Natixis Invests $2.13 Million in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Immunome (NASDAQ:IMNM) Reaches New 1-Year HighTime to Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Hits New 12-Month HighHere's Why - MarketBeat
Immunome stock hits 52-week high at $20.50 - Investing.com
Marshall Wace LLP Sells 312,956 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunome, Inc. (IMNM) -6.5% in After-hours: What’s Driving the Move? - Stocks Telegraph
Can Immunome Inc stock deliver strong Q4 earningsTrade Volume Report & Risk Managed Investment Signals - moha.gov.vn
What drives Immunome Inc stock priceEarnings Surprise Analysis & Make Confident Moves With Forecasting Models - earlytimes.in
Understanding Momentum Shifts in (IMNM) - news.stocktradersdaily.com
Is Immunome Inc (IMNM) positioned for future growth? - setenews.com
Kennedy Capital Management LLC Purchases 94,627 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome initiated with a Buy at Truist - MSN
Tema Etfs LLC Takes $1.07 Million Position in Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome (NASDAQ:IMNM) Stock Price Up 9.5%Time to Buy? - MarketBeat
Is Immunome Inc a good long term investmentSwing Trading Ideas & Superior Capital Appreciation - earlytimes.in
Immunome (NASDAQ:IMNM) Hits New 1-Year HighShould You Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Trading Down 6.7%Here's Why - MarketBeat
Immunome stock hits 52-week high at 19.16 USD By Investing.com - Investing.com Australia
Immunome stock hits 52-week high at 19.16 USD - Investing.com
It makes sense and dollars to buy Immunome Inc (IMNM) stock - setenews.com
Truist Financial Initiates Coverage on Immunome (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Truist Financial - Defense World
Immunome (IMNM) Stock Analysis Report | Financials & Insights - Benzinga
Truist Securities initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com South Africa
IMNM: Truist Securities Initiates Coverage with 'Buy' Rating and - GuruFocus
Truist Securities initiates coverage on Immunome stock with Buy rating - Investing.com India
Truist Initiates Immunome at Buy With $36 Price Target - marketscreener.com
Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM - Defense World
Geode Capital Management LLC Has $17.31 Million Stock Holdings in Immunome, Inc. $IMNM - MarketBeat
Avoiding Lag: Real-Time Signals in (IMNM) Movement - news.stocktradersdaily.com
How institutional buying supports Immunome Inc. stock2025 Trading Recap & Real-Time Stock Entry Alerts - moha.gov.vn
Immunome Inc Stock Analysis and ForecastSell Signals and Alerts & Free Proven Portfolio Growth Strategies - earlytimes.in
Immunome to Present at Upcoming December 2025 Investor Conferences - BioSpace
Immunome (NASDAQ:IMNM) Sets New 12-Month HighHere's Why - MarketBeat
Immunome Inc (IMNM) is looking forward to a strong quarter - Setenews
Immunome to Present at Upcoming Investor Conferences - marketscreener.com
Immunome (NASDAQ: IMNM) to present Dec. 3 at Piper Sandler and Evercore conferences - Stock Titan
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤놈 주식 (IMNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
1.08%
0.91%
자본화:
|
볼륨(24시간):